HC Wainwright Estimates Pharming Group Q3 Earnings

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Investment analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for shares of Pharming Group in a report released on Thursday, March 12th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of $0.12 for the quarter. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group’s FY2027 earnings at $0.69 EPS.

A number of other research analysts also recently issued reports on the company. Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a report on Thursday. Weiss Ratings lowered shares of Pharming Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. Wall Street Zen upgraded shares of Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Finally, Oppenheimer reissued an “outperform” rating and set a $41.00 price target (down from $42.00) on shares of Pharming Group in a report on Friday. Two equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Pharming Group presently has a consensus rating of “Hold” and a consensus price target of $39.00.

Pharming Group Stock Down 4.2%

Pharming Group stock opened at $14.51 on Monday. The business’s 50-day moving average price is $17.21 and its 200 day moving average price is $16.09. The company has a quick ratio of 2.03, a current ratio of 2.59 and a debt-to-equity ratio of 0.33. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of 1,451.00 and a beta of 0.04. Pharming Group has a 52 week low of $7.50 and a 52 week high of $21.34.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings data on Thursday, March 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08). The company had revenue of $106.50 million for the quarter, compared to analysts’ expectations of $111.76 million. Pharming Group had a net margin of 0.71% and a return on equity of 1.08%.

Hedge Funds Weigh In On Pharming Group

Several hedge funds and other institutional investors have recently made changes to their positions in PHAR. EverSource Wealth Advisors LLC acquired a new stake in shares of Pharming Group in the second quarter worth approximately $32,000. SmartHarvest Portfolios LLC acquired a new position in Pharming Group in the 4th quarter valued at $224,000. Millennium Management LLC purchased a new position in Pharming Group in the 4th quarter valued at $360,000. Finally, NewEdge Advisors LLC lifted its holdings in Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares in the last quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.

More Pharming Group News

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Company set a 2026 revenue target of $405M–$425M, citing growth from Joenja and RUCONEST as primary drivers — this provides clear growth levers for next year and supports upside if execution meets targets. Pharming outlines $405M–$425M 2026 revenue target
• Positive Sentiment: Company reported full-year and Q4 2025 revenue growth and positive cash flow and reaffirmed 2026 guidance — fundamentals showing improving cash generation can reduce funding risk and support valuation. Pharming Group reports fourth quarter and full year 2025 financial results
• Positive Sentiment: Oppenheimer reiterated an “Outperform” rating with a $41 price target (slightly trimmed), signaling continued bullish analyst conviction and implying substantial upside from current levels. Oppenheimer reaffirms outperform on PHAR
• Neutral Sentiment: HC Wainwright maintains a Buy rating and $37 target but lowered FY2026 EPS from $0.49 to $0.35 — the firm still expects material 2026 profitability, but the cut shows some model uncertainty around timing and magnitude of margin expansion. HC Wainwright updates estimates for PHAR
• Negative Sentiment: Q4 results missed expectations: revenue $106.5M vs. analyst ~$111.8M and EPS $0.07 vs. $0.15 expected — the quarter’s misses likely triggered the intraday sell-off despite upbeat guidance. Pharming Q4 2025 press release

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.